![Jump to content [Access key 'm']](/siteware/cleardot.gif){kind=small}
Management Team
 Spiro
Rombotis |
Paul
McBarron |
Gregory Reyes, M.D., Ph.D. |
| Professor
David Glover, FRSE |
Judy
Chiao, M.D. |
Gill Christie |
| Susan
Davis, Ph.D. |
John Womelsdorf, Ph.D. |
|
Spiro Rombotis
President and Chief Executive Officer, Director
Mr. Rombotis joined Cyclacel in August 1997 and has over 24 years of experience with pharmaceutical and biotechnology companies.
He was previously Vice President of International Operations and Business Development, Managing Director, Europe and Director, Japanese joint venture, at The Liposome Company, Inc. Mr. Rombotis also served as Vice President of Pharmaceuticals for Central and Eastern Europe and as Director of International Marketing at Bristol-Myers Squibb Company.
He was Head of European Marketing and Sales and Head of Corporate Development at Centocor, Inc. as well as working in Business Development at Novartis AG. He holds a B.A. from Williams College and an M.B.A. and Master’s degree in Hospital Management with honors, from the Kellogg Graduate School of Management where he serves on the Kellogg Biotech Advisory Board.
Paul McBarron
Executive Vice President, Finance and Chief Operating Officer, Secretary and Director
Mr. McBarron joined Cyclacel in January 2002 with over 15 years of experience as a financial executive with several pharmaceutical companies. Since 1996 he was a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller.
He joined Shire when it was an emerging public company employing less than 100 people. He was previously employed in various financial positions at Sterling Drug and SmithKline Beecham and qualified as a chartered accountant with Ernst & Young.
Gregory Reyes, M.D., Ph.D.
Senior Vice President, Research
Dr. Reyes joined Cyclacel in June, 2007. He has over 20 years of senior leadership experience in both large pharma and biotech, most recently as the Vice President Discovery Biology with Pfizer Global Research and Development (Ann Arbor, MI). Prior to Pfizer, Dr. Reyes served as Vice President, Biological Research, Infectious Diseases and Tumor Biology at Schering-Plough Research Institute (SPRI). While at Schering-Plough, his group advanced 14 new drug candidates in oncology and anti-infectives into preclinical and clinical development. Prior to Schering-Plough Dr. Reyes served as Vice President, Research and Development at Ingenex, Inc., Vice President, Molecular and Biological Research at Triplex Pharmaceuticals, Inc. and Vice President, Hepatitis Research at GeneLabs, Inc. Over his career he has nearly 100 publications and nearly 50 granted patents.
Dr. Reyes earned his B.A. summa cum laude in Biology from the University of California at Santa Cruz and his M.D. and Ph.D. from The Johns Hopkins School of Medicine in 1982. He completed his medical internship at Stanford University Hospital in 1983 and was a Damon Runyon-Walter Winchell Cancer Fund Fellow at Stanford University School of Medicine’s Cancer Biology Research Lab. He has received numerous awards and distinctions and was recently appointed by the Director of the National Institutes of Health (NIH) to the National Advisory General Medical Sciences Council for a three year term ending in December 2007.
Professor David Glover, FRSE
Chief Scientist, Polgen Division
Professor Glover joined Cyclacel in November 1999. He is Arthur Balfour Professor of Genetics and Chairman in the Department of Genetics at the University of Cambridge. He is also Director of Cancer Research UK Cell Cycle Genetics Research Group.
He was previously Professor of Molecular Genetics at the University of Dundee and Professor and Head of Biochemistry at Imperial College, London. Professor Glover discovered and named the Polo and Aurora mitotic protein kinases and co-ordinated the former European Drosophila Genome Project, the European academic consortium contributing to sequencing the fruit fly genome.
He is a member of the European Molecular Biology Oncology and has authored over 200 publications and patents.
Judy Chiao, M.D.Vice President Clinical Development and Regulatory Affairs
Dr. Chiao joined Cyclacel in December, 2004. She was previously Vice President, Oncology Clinical Research and Development at Aton Pharma Inc, a wholly owned subsidiary of Merck & Co. Prior to Aton's acquisition by Merck she was responsible for leading the clinical development of SAHA, a histone deacetylase inhibitor, in Phase II development for hematologic and solid tumor indications.
She was a Senior Medical Reviewer, Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, where she was the agency's primary reviewer for a range of oncology drugs and regulatory subjects. She also presented the FDA's views in several New Drug Application reviews at Oncology Drug Advisory Committees.
Dr. Chiao earned her Bachelor of Science in Chemistry (summa cum laude) at Columbia University, New York, and received her medical degree from Harvard Medical School. Her internship and residency in internal medicine was carried out at Columbia-Presbyterian Medical Center, New York and she held a Research Fellowship in Molecular Pharmacology at Sloan Kettering Institute for Cancer Research and a Clinical Fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center, both in New York City.
She has also been a member of a number of FDA related working groups and has also been a Core Member of the Pharsight-FDA Cooperative Research and Development Agreement (CRADA) on clinical trial simulation and population pharmacokinetic analysis software for drug development.
Gill Christie
Director, Human Resources
Ms. Christie joined Cyclacel in January 2001. She was previously Human Resources
Manager with
Susan Davis, Ph.D.
Associate Director, Business Development
Dr. Davis joined Cyclacel in September 2000. She was previously Business Development Manager, Fluorescience Ltd.; Group Leader Screening, RiboGene, Inc. (now Questcor Pharmaceuticals, Inc.) where she played a key role in HTS-centered anti-infective research collaborations with Abbott Pharmaceuticals and Dainippon; and Project Leader, Biochemical Research, Sandoz Chemicals Ltd. She holds a Ph.D. in Biochemistry from the University of Kent at Canterbury and a B.Sc. in Applied Biology from the University of Wales.
John Womelsdorf, Ph.D.
Vice President, Business Development
Dr. Womelsdorf joined Cyclacel in August 2006 and has more than 20 years experience in business development roles at Hoffmann-La Roche, Baxter International and, most recently, Johnson & Johnson (J&J) where he served as Executive Director, Licensing and New Business Development of the Pharmaceuticals Group. Prior to joining J&J, Dr. Womelsdorf worked as a Global Licensing Director for F. Hoffmann-La Roche, Inc. He was previously a Business Development Fellow at Baxter International, Inc. where he worked closely with Research and Development licensing in early technologies. Dr. Womelsdorf earned his Bachelor of Science degree in 1988 and his Ph.D. in Physical Chemistry in 1993 from Stevens Institute of Technology. He also earned an M.B.A. from Columbia University in 1997.
